139 related articles for article (PubMed ID: 38165064)
1. Long-term treatment with fostamatinib in Japanese patients with primary immune thrombocytopenia: An open-label extension study following a phase 3 placebo-controlled, double-blind, parallel-group study.
Kuwana M; Ito T; Kowata S; Hatta Y; Fujimaki K; Naito K; Kurahashi S; Kagoo T; Tanimoto K; Saotome S; Tomiyama Y
Am J Hematol; 2024 Feb; 99(2):E55-E59. PubMed ID: 38165064
[No Abstract] [Full Text] [Related]
2. Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program.
Bussel JB; Arnold DM; Boxer MA; Cooper N; Mayer J; Zayed H; Tong S; Duliege AM
Am J Hematol; 2019 May; 94(5):546-553. PubMed ID: 30784097
[TBL] [Abstract][Full Text] [Related]
3. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials.
Bussel J; Arnold DM; Grossbard E; Mayer J; Treliński J; Homenda W; Hellmann A; Windyga J; Sivcheva L; Khalafallah AA; Zaja F; Cooper N; Markovtsov V; Zayed H; Duliege AM
Am J Hematol; 2018 Jul; 93(7):921-930. PubMed ID: 29696684
[TBL] [Abstract][Full Text] [Related]
4. Real-World Use of Fostamatinib in Patients with Immune Thrombocytopenia and Thrombotic Risk.
Mehta AR; Kefela A; Toste C; Sweet D
Acta Haematol; 2022; 145(2):221-228. PubMed ID: 34913873
[TBL] [Abstract][Full Text] [Related]
5. Fostamatinib for the treatment of Japanese patients with primary immune thrombocytopenia: A phase 3, placebo-controlled, double-blind, parallel-group study.
Kuwana M; Ito T; Kowata S; Hatta Y; Fujimaki K; Naito K; Kurahashi S; Kagoo T; Tanimoto K; Saotome S; Tomiyama Y;
Br J Haematol; 2023 Mar; 200(6):802-811. PubMed ID: 36470677
[TBL] [Abstract][Full Text] [Related]
6. Treatment with fostamatinib in patients with immune thrombocytopenia: Experience from the Andalusian region in Spain-The Fostasur Study.
Jiménez-Bárcenas R; García-Donas-Gabaldón G; Campos-Álvarez RM; Fernández-Sánchez de Mora MC; Luis-Navarro J; Domínguez-Rodríguez JF; Nieto-Hernández MDM; Sánchez-Bazán I; Yera-Cobo M; Cardesa-Cabrera R; Jiménez-Gonzalo FJ; Ruiz-Cobo MA; Caparrós-Miranda I; Entrena-Ureña L; Fernández Jiménez D; Díaz-Canales D; Moreno-Carrasco G; Calderón-Cabrera C; Núñez-Vázquez RJ; Pedrote-Amador B; Mingot-Castellano ME;
Br J Haematol; 2024 May; 204(5):1977-1985. PubMed ID: 38566598
[TBL] [Abstract][Full Text] [Related]
7. Fostamatinib: A Review in Chronic Immune Thrombocytopenia.
Paik J
Drugs; 2021 Jun; 81(8):935-943. PubMed ID: 33970459
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the disposition of fostamatinib in Japanese subjects including pharmacokinetic assessment in dry blood spots: results from two phase I clinical studies.
Martin P; Cheung SY; Yen M; Han D; Gillen M
Eur J Clin Pharmacol; 2016 Jan; 72(1):61-71. PubMed ID: 26490353
[TBL] [Abstract][Full Text] [Related]
9. Evaluating fostamatinib disodium as a treatment option for immune thrombocytopenia in adult patients.
Dierickx D; Neefs J
Expert Opin Pharmacother; 2022 Jun; 23(8):885-892. PubMed ID: 35621338
[TBL] [Abstract][Full Text] [Related]
10. Fostamatinib: a review of its clinical efficacy and safety in the management of chronic adult immune thrombocytopenia.
Newland A; McDonald V
Immunotherapy; 2020 Dec; 12(18):1325-1340. PubMed ID: 33023353
[TBL] [Abstract][Full Text] [Related]
11. Fostamatinib: First Global Approval.
Markham A
Drugs; 2018 Jun; 78(9):959-963. PubMed ID: 29869203
[TBL] [Abstract][Full Text] [Related]
12. Fostamatinib for the Treatment of Hospitalized Adults With Coronavirus Disease 2019: A Randomized Trial.
Strich JR; Tian X; Samour M; King CS; Shlobin O; Reger R; Cohen J; Ahmad K; Brown AW; Khangoora V; Aryal S; Migdady Y; Kyte JJ; Joo J; Hays R; Collins AC; Battle E; Valdez J; Rivero J; Kim IH; Erb-Alvarez J; Shalhoub R; Chakraborty M; Wong S; Colton B; Ramos-Benitez MJ; Warner S; Chertow DS; Olivier KN; Aue G; Davey RT; Suffredini AF; Childs RW; Nathan SD
Clin Infect Dis; 2022 Aug; 75(1):e491-e498. PubMed ID: 34467402
[TBL] [Abstract][Full Text] [Related]
13. Addressing thrombosis concerns in immune thrombocytopenia: the role of fostamatinib in immune thrombocytopenia management.
Provan D; Thachil J; Álvarez Román MT
Expert Rev Hematol; 2024; 17(1-3):55-66. PubMed ID: 38369947
[TBL] [Abstract][Full Text] [Related]
14. Clinical Pharmacokinetics and Pharmacodynamics of Fostamatinib and Its Active Moiety R406.
Matsukane R; Suetsugu K; Hirota T; Ieiri I
Clin Pharmacokinet; 2022 Jul; 61(7):955-972. PubMed ID: 35781630
[TBL] [Abstract][Full Text] [Related]
15. Fostamatinib combined with TPO-RAs or steroids as a bridge to monotherapy or as time-limited continuous treatment in relapsed chronic ITP: A single-centre case series.
Passucci M; Laganà A; Donzelli L; Masucci C; Genoese A; Chistolini A; Baldacci E; Santoro C
Br J Haematol; 2024 May; 204(5):2129-2132. PubMed ID: 38563350
[No Abstract] [Full Text] [Related]
16. Fostamatinib is an effective second-line therapy in patients with immune thrombocytopenia.
Boccia R; Cooper N; Ghanima W; Boxer MA; Hill QA; Sholzberg M; Tarantino MD; Todd LK; Tong S; Bussel JB;
Br J Haematol; 2020 Sep; 190(6):933-938. PubMed ID: 33439486
[TBL] [Abstract][Full Text] [Related]
17. Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia: Phase 2, multicenter, open-label study.
Kuter DJ; Rogers KA; Boxer MA; Choi M; Agajanian R; Arnold DM; Broome CM; Field JJ; Murakhovskaya I; Numerof R; Tong S
Am J Hematol; 2022 Jun; 97(6):691-699. PubMed ID: 35179251
[TBL] [Abstract][Full Text] [Related]
18. Fostamatinib for the treatment of immune thrombocytopenia in adults.
Moore DC; Gebru T; Muslimani A
Am J Health Syst Pharm; 2019 May; 76(11):789-794. PubMed ID: 30951590
[TBL] [Abstract][Full Text] [Related]
19. Spleen tyrosine kinase inhibitors for rheumatoid arthritis: where are we now?
Scott IC; Scott DL
Drugs; 2014 Mar; 74(4):415-22. PubMed ID: 24610702
[TBL] [Abstract][Full Text] [Related]
20. A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 2 dosing regimens of fostamatinib in patients with rheumatoid arthritis with an inadequate response to a tumor necrosis factor-α antagonist.
Genovese MC; van der Heijde DM; Keystone EC; Spindler AJ; Benhamou C; Kavanaugh A; Fudman E; Lampl K; O'Brien C; Duffield EL; Poiley J; Weinblatt ME
J Rheumatol; 2014 Nov; 41(11):2120-8. PubMed ID: 25225285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]